<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02572700</url>
  </required_header>
  <id_info>
    <org_study_id>H-15009080</org_study_id>
    <nct_id>NCT02572700</nct_id>
  </id_info>
  <brief_title>Pain Mechanisms and Ultrasonographic Disease Activity in Psoriatic Arthritis</brief_title>
  <acronym>PIPA</acronym>
  <official_title>Pain Mechanisms and Ultrasonographic Inflammatory Changes as Prognostic Factors in Patients With Psoriatic Arthritis: a Prospective, Exploratory Cohort Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Frederiksberg University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Frederiksberg University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of the study is to investigate pain mechanisms, comorbidity status, biomarkers,&#xD;
      patient reported outcome measures, ultrasonographic (US) inflammatory activity and&#xD;
      association between these features in patients with psoriatic arthritis (PsA) intensifying&#xD;
      anti-rheumatic treatment. Furthermore, to assess the predictive value of baseline pain&#xD;
      profile, comorbidity status, and US joint/entheses activity on treatment outcome after 4&#xD;
      months. Finally, we aimed to compare baseline characteristics with I) patients with skin&#xD;
      psoriasis without arthritis and II) healthy controls.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with psoriatic arthritis, who initiate or switch anti-rheumatic treatment&#xD;
      (conventional disease modifying drugs or biologic drugs) in routine care due to an active&#xD;
      disease state, will be enrolled in the observational study.&#xD;
&#xD;
      The overall aim is to investigate pain mechanisms, comorbidities and US psoriatic changes and&#xD;
      elucidate if these factors - independently or by interaction - influence treatment response&#xD;
      after 4 months. Patients will have a baseline visit, a follow up visit after 4 months and&#xD;
      yearly thereafter. Examinations will be performed at all time points (except stated&#xD;
      otherwise) and include:&#xD;
&#xD;
        1. Assessment of pain mechanisms by clinical evaluation (swollen/tender joint ratio, tender&#xD;
           points) and pain questionnaires (widespread pain index, PainDETECT).&#xD;
&#xD;
        2. Ultrasonography of joints and entheses by two trained assessors&#xD;
&#xD;
        3. Clinical examination of all psoriatic manifestations&#xD;
&#xD;
        4. Interview and questionnaires regarding lifestyle, comorbidity status, function, quality&#xD;
           of life and the impact of psoriatic manifestations.&#xD;
&#xD;
        5. Blood samples for standard rheumatic monitoring and biobank&#xD;
&#xD;
        6. X-ray of hands and feet (only at baseline)&#xD;
&#xD;
        7. AMPS test (assessment of motor and process skills) will be performed and interpreted by&#xD;
           an certified ergo therapist (only at baseline visit and at 34-months follow-up and oly&#xD;
           for the first included 20 PsA patients)&#xD;
&#xD;
      Clinical as well as patient-reported and observer-based outcomes will be described for the&#xD;
      overall study population and the prognostic influence of US, comorbidities, and pain&#xD;
      mechanisms will be analysed. Subsequently, the analyses will be repeated for certain&#xD;
      subgroups of patients (e.g., conventional drug therapy vs. biologic drug intervention) in an&#xD;
      exploratory manner. We will compare baseline data including pain, fatigue, work, life style&#xD;
      and comorbidity status of PsA patients before initiating new treatment with patients with&#xD;
      skin psoriasis without arthritis and healthy controls&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 2015</start_date>
  <completion_date type="Anticipated">September 2025</completion_date>
  <primary_completion_date type="Anticipated">September 2025</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>American college of rheumatology 20%,</measure>
    <time_frame>4 months from baseline</time_frame>
    <description>Composite measures of improvement in disease state (20% improvement)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease Activity Index in Psoriatic Arthritis (DAPSA)</measure>
    <time_frame>4 months from baseline</time_frame>
    <description>A composite measure of disease activity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minimal Disease Activity (MDA)</measure>
    <time_frame>4 months from baseline</time_frame>
    <description>A composite measure of disease activity</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Change in swollen joint count (SJC)</measure>
    <time_frame>4 months from baseline</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change in tender joint count (TJC)</measure>
    <time_frame>4 months from baseline</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change in Spondyloarthritis Research Consortium of Canada enthesitis score (SPARCC)</measure>
    <time_frame>4 months from baseline</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change in The Psoriatic Arthritis Impact of Disease-score (PsAID)</measure>
    <time_frame>4 months from baseline</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change in Dermatology Life Quality Index (DLQI)</measure>
    <time_frame>4 months from baseline</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change in Assessment of Motor and Process Skills (AMPS test)</measure>
    <time_frame>4 months from baseline</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Transition Questionnaire score (Trans-Q)</measure>
    <time_frame>4 months from baseline</time_frame>
    <description>Patient's judgement of overall improvement during treatment</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in PainDETECTquestionnaire score (PDQ)</measure>
    <time_frame>4 months from baseline</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change in Health Assessment Questionnaire disability index (HAQ)</measure>
    <time_frame>4 months from baseline</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change in Visual Analogue Scale (VAS) (0-100 mm) of fatigue</measure>
    <time_frame>4 months from baseline</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change in Visual Analogue Scale (VAS) (0-100 mm) of pain</measure>
    <time_frame>4 months from baseline</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change in Visual Analogue Scale (VAS) (0-100 mm) of global disease impact</measure>
    <time_frame>4 months from baseline</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change in score of Medical Outcomes Study Questionnaire (SF-36) for mental and physical health</measure>
    <time_frame>4 months from baseline</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change in psoriasis area severity index (PASI)</measure>
    <time_frame>4 months from baseline</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change in ultrasonography joint scores (grey scale and doppler)</measure>
    <time_frame>4 months from baseline</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change in ultrasonography entheses scores (grey scale and doppler)</measure>
    <time_frame>4 months from baseline</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change in total cholesterol (mmol/L)</measure>
    <time_frame>4 months from baseline</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change in body weight (kg)</measure>
    <time_frame>4 months from baseline</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change in c-reactive protein (mg/L)</measure>
    <time_frame>4 months from baseline</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI)</measure>
    <time_frame>4 months from baseline</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change in Bath Ankylosing Spondylitis Functional Index (BASFI)</measure>
    <time_frame>4 months from baseline</time_frame>
  </other_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Psoriatic Arthritis</condition>
  <condition>Psoriasis</condition>
  <condition>Healthy Controls</condition>
  <arm_group>
    <arm_group_label>Patients with psoriatic arthritis</arm_group_label>
    <description>PsA patients initiating anti-rheumatic treatment in routine care will be included as one group in the observational study. Analyses will be carried out for the overall study population as well as for subgroups (e.g., stratified according to treatment intervention) in an exploratory manner.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients with skin psoriasis without arthrits</arm_group_label>
    <description>20 patients with skin psoriasis without arthrits will be included as one group at baseline only. Baseline characteristics including status of pain, fatigue, work, comorbidity and lifestyle factors will be recorded.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy controls</arm_group_label>
    <description>20 healthy controls will be included as one group at baseline only. Baseline characteristics including status of pain, fatigue, work, comorbidity and lifestyle factors will be recorded.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Clinical examination, blood sampling, ultrasonic assessment, and questionnaires</intervention_name>
    <description>Visits include clinical examination, questionnaires (pain, comorbidity, lifestyle, work status) and ultrasonography of joints and entheses, blood samples, and only at baseline x-ray of hands and feet.</description>
    <arm_group_label>Healthy controls</arm_group_label>
    <arm_group_label>Patients with psoriatic arthritis</arm_group_label>
    <arm_group_label>Patients with skin psoriasis without arthrits</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood are processed for storage in a project biobank including plasma, serum and blood&#xD;
      leucocytes for assessment of immune characteristics and mechanisms&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        &gt; 18 years of age with PsA according to the CASPAR criteria who initiate or switch&#xD;
        anti-rheumatic treatment (biologics and/or conventional synthetic DMARDs) due to active PsA&#xD;
        in routine care.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosed with PsA according to the CASPAR (The Classification of Psoriatic Arthritis)&#xD;
             criteria&#xD;
&#xD;
          -  Peripheral joint involvement.&#xD;
&#xD;
          -  Minimum 18 years of age.&#xD;
&#xD;
          -  Initiating or switching anti-rheumatic treatment due to active PsA.&#xD;
&#xD;
          -  Signing a written informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Peripheral neuropathy&#xD;
&#xD;
          -  Demyelinising disease&#xD;
&#xD;
          -  Recent stroke&#xD;
&#xD;
          -  Other rheumatic inflammatory diseases.&#xD;
&#xD;
          -  Oral, intra-articular or intra-muscular glucocorticoids within 3 weeks prior to&#xD;
             baseline&#xD;
&#xD;
          -  Treatment with centrally acting analgesics (opioids, anti-depressants,&#xD;
             anticonvulsants) within 1 week prior to baseline&#xD;
&#xD;
          -  Treatment with mild analgesics (non-steroidal anti-inflammatory drugs, acetylsalicylic&#xD;
             acid, acetaminophen) within 24 hours prior to baseline&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lars Erik Kristensen, MD, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Parker Institute, Frederiksberg and Bispebjerg Hospital, Frederiksberg, Denmark</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Zara R Stisen, MD</last_name>
    <phone>0045 3816 4178</phone>
    <email>zara.rebecca.stisen.03@regionh.dk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Marie Skougaard, MD</last_name>
    <phone>0045 38164178</phone>
    <email>marie.skougaard@regionh.dk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The Parker Institute, Frederiksberg and Bispebjerg Hospital</name>
      <address>
        <city>Frederiksberg</city>
        <state>Copenhagen</state>
        <zip>2000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zara R Stisen, MD</last_name>
      <phone>38164178</phone>
      <phone_ext>0045</phone_ext>
      <email>marie.skougaard.nielsen@regionh.dk</email>
    </contact>
    <contact_backup>
      <last_name>Lars Erik Kristensen, MD, phd</last_name>
      <phone>38164157</phone>
      <phone_ext>0045</phone_ext>
      <email>lars.erik.kristensen@regionh.dk</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>October 2, 2015</study_first_submitted>
  <study_first_submitted_qc>October 8, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 9, 2015</study_first_posted>
  <last_update_submitted>March 3, 2021</last_update_submitted>
  <last_update_submitted_qc>March 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital Bispebjerg and Frederiksberg</investigator_affiliation>
    <investigator_full_name>Henning Bliddal</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Psoriatic arthritis</keyword>
  <keyword>Psoriasis</keyword>
  <keyword>DMARD</keyword>
  <keyword>Pain</keyword>
  <keyword>Comorbidities</keyword>
  <keyword>Ultrasound</keyword>
  <keyword>Immunology</keyword>
  <keyword>Patient-reported outcomes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Psoriatic</mesh_term>
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

